Faisal Khurshid
Stock Analyst at Leerink Partners
(2.00)
# 2,945
Out of 4,868 analysts
19
Total ratings
50%
Success rate
-8.13%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.70 | +43.10% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $15.08 | +198.41% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $11.62 | +37.69% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.97 | +310.51% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.31 | +52.67% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $5.17 | +209.48% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $46.44 | +29.20% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $64.66 | +23.72% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.11 | +1,251.35% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $6.07 | +15.32% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.90 | +151.40% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $28.31 | -15.22% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.55 | +351.61% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.81 | +109.97% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.75 | +569.88% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.05 | +260.66% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.70
Upside: +43.10%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $15.08
Upside: +198.41%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $11.62
Upside: +37.69%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.97
Upside: +310.51%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.31
Upside: +52.67%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $5.17
Upside: +209.48%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $46.44
Upside: +29.20%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $64.66
Upside: +23.72%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.11
Upside: +1,251.35%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.07
Upside: +15.32%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.90
Upside: +151.40%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $28.31
Upside: -15.22%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.55
Upside: +351.61%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.81
Upside: +109.97%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.75
Upside: +569.88%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.05
Upside: +260.66%